Combination therapeutic approach for asthma and allergic rhinitis

Current Clinical Pharmacology

Volumn 3, Issue 3, 2008, Pages 185-197

  Chauhan, Bhupendrasinh ^a   Patel, Madhabhai ^b   Padh, Harish ^a   Nivsarkar, Manish ^a  

^a B V PATEL PHARMACEUTICAL EDUCATION AND RESEARCH DEVELOPMENT PERD CENTRE   (India)

^b S K Patel College of Pharmacy and Research Centre   (India)

Author keywords

Allergic rhinitis; Asthma; Cinical trial; Combination therapy

Indexed keywords

AMINOPHYLLINE; BECLOMETASONE; BUDESONIDE; CETIRIZINE; CROMOGLYCATE DISODIUM; DEXAMETHASONE; FENOTEROL; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; HISTAMINE; IMMUNOGLOBULIN E; IPRATROPIUM BROMIDE; LEUKOTRIENE; LORATADINE; MONTELUKAST; NEDOCROMIL; OMALIZUMAB; OXITROPIUM BROMIDE; PHENYLEPHRINE; PLACEBO; PREDNISONE; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; THROMBOCYTE ACTIVATING FACTOR; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; ZAFIRLUKAST; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DECONGESTIVE AGENT;

ADD ON THERAPY; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; B LYMPHOCYTE; BINDING AFFINITY; BRONCHODILATATION; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; EOSINOPHIL; HUMAN; INFLAMMATORY CELL; MACROPHAGE; MAST CELL; MEDICAL DECISION MAKING; MEDLINE; NEUTROPHIL; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR BINDING; REVIEW; TH2 CELL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; ECONOMICS; HAY FEVER; PERENNIAL RHINITIS;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; HISTAMINE ANTAGONISTS; HUMANS; NASAL DECONGESTANTS; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 58149139509     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488408785747700     Document Type: Review

References (126)

1. Grossman J. One airway, one disease. Chest 1997; 111: 11-6.
2. Corren J. Allergic rhinitis and asthma: how important is the link? J Allergy Clin Immunol 1997; 99: 781-6.
3. Smith JM. Epidemiology and natural history of asthma, allergic rhinitis, and atopic dematitis (eczema). In: Middleton E Jr, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW, Eds. Allergy: Principles and Practices. IIIrd ed; St Louis: CV Mosby; 1996; 891-929.
4. Kapsali T, Horowitz E, Togias A. Rhinitis is ubiquitous in allergic asthmatics (abstract). J Allergy Clin Immunol 1997; 99: S138.
5. Blair H. Natural history of childhood asthma: 20-year follow-up. Arch Dis Child 1977; 52: 613-9.
6. Foresi A, Pelucchi A, Gherson G, Mastropasqua B, Chiapparino A, Testi R. Once daily intranasal fluticasone propionate (200 μg) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 1996; 98: 274-82.
7. Busse WW. Asthma. N Engl J Med 2001; 344: 350-62.
8. Maddox L, Schwartz DA. The pathophysiology of asthma. Annu Rev Med 2002; 53: 477-98.
9. Wei Duan I, Chun Kuo, Sathiyamoorthy S, Kaw YC, Boon HB, Fred Wong WS. Antiinflammatory effects of genistein, a tyrosine kinase inhibitor, on a guinea pig model of asthma. Am J Respir Crit Care Med 2003; 167: 185-92.
10. Antonio MV, Franco M, Giorgio C, et al. Airway Remodeling in Asthma. Chest 2003; 123: 417-22.
11. Lund VJ, Aaronson D, Bousquet J. International consensus report on the diagnosis and management of rhinitis. Allergy 1994; 49: 1-34.
12. Metzget WJ, Richerson HB, Worden K, Monick M, Hunninghake GW. Bronchoalveolar lavage of allergic asthmatic patients following allergen bronchoprovocation. Chest 1986; 89: 477-83.
13. Barnes PJ. Pathophysiology of asthma. Br J Clin Pharmacol 1996; 42: 3-10.
14. Jatakanon A, Uasuf C, Maziak W, Lim S, Fan Chung K, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160: 1532-9.
15. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990; 142: 434-57.
16. Galli SJ. Complexity and redundancy in the pathogenesis of asthma: reassessing the roles of mast celIs and T cells. J Exp Med 1997; 186: 343-7.
17. O'Byme PM, Dolovich J, Hargreave FE. Late asthmatic responses. Am Rev Respir Dis 1997; 136: 740-51.
18. Djukanovic R, Wilson JW, Britten KM, et al. Quantitation of mast cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry. Am Rev Respir Dis 1990; 142: 863-71.
19. Wardlaw AJ, Dunnette S, Gleich GJ, Collins JV, Kay AB. Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma: relationship to bronchial hyperreactivity. Am Rev Respir Dis 1998; 137: 62-9.
20. Pin I, Gibson PJ, Kolendowicz R, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992; 47: 25-9.
21. Gibson PG, Wlodarczyk JW, Hensley MJ, et al. Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood. Am J Respir Crit Care Med 1998; 158: 36-41.
22. Cai Y, Wlodarczyk JW, Henry RL, Gibson PG. Persistence of sputum eosinophilia in children with controlled asthma when compared with healthy children. Eur Respir J 1998; 11: 848-53.
23. Banner KH. Ovalbumin challenge following immunization elicits recruitment of eosinophils but not bronchial hyperresponsiveness in guinea-pigs: time course and relationship to eosinophil activation status. Pulm Pharmacol 1996; 9: 179-87.
24. Lefort J, Nahori MA, Ruffle C, Vargaftig BB, Pretolani M. In vivo neutralization of eosinophil-derived major basic protein inhibits antigen induced bronchial hyperreactivity in sensitized guinea pigs. J Clin Invest 1994; 97: 1117-21.
25. Ohnuki LE, Wagner LA, Georgelas A, et al. Differential extraction of eosinophil granule proteins. J Immunol Methods 2005; 307: 54-61.
26. Kandil AA, Hasan A, Taha O, El-Mesallamy H. Eosinophil cationic protein as a diagnostic marker for asthmatic children treated by immunotherapy. Egypt J Immunol 2003; 10: 67-76.
27. Brusasco V. Airway hyperresponsiveness in asthma: not just a matter of airway inflammation. Thorax 1998; 53: 992-8.
28. Ordonez CL, Shaughnessy TE, Matthay MA, Fahy JV. Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: clinical and biologic significance. Am J Respir Crit Care Med 2000; 161: 1185-90.
29. Schleimer RP, MacGlashan DW Jr, Peters SP, et al. Inflammatory mediators and mechanism of release from purified human basophils and mast cells. J Allergy Clin Immunol 1984; 74: 473-81.
30. Holgate ST, Hardy CC, Robinson C, Agius RM, Howarth PH. The mast cell as a primary effector cell in the pathogenesis of asthma. J Allergy Clin Immunol 1986; 77: 274-82.
31. Iliopoulos O, Baroody FM, Naclerio RM, Bochner BS, Kagey-Sobotka A, Lichtenstein LM. Histamine containing cells obtained form the nose hours after antigen challenge have functional and phenotypic characteristics of basophils. J Immunol 1992; 148: 2223-8.
32. Barnes PJ, Chung KF and Page CP. Inflammatory mediators of asthma: an update. Pharmacol Rev 1998; 50: 515-96.
33. Schroder JT and MacGlashan DW. New concepts: The basophil. J Allergy Clin Immunol 1997; 99: 429-33.
34. Mygind N. Mediators of nasal allergy. J Allergy Clin Immunol 1982; 70: 149-59.
35. Chishty M, Reichel A, Siva J, Abbott NJ, Begley DJ. Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines. J Drug Target 2001; 9: 223-8.
36. 1-antagonists. Drug Metab Dispos 2003; 31: 312-8.
37. Tashiro M, Mochizuki H, Iwabuchi K, et al. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci 2002; 72: 409-14.
38. Simons FE. Non-cardiac adverse effects of antihistamines (H1-receptor antagonists). Clin & Exp Allergy 1999; 29: 125-32.
39. Welch MJ, Meltzer EO, Simons FE. H1-antihistamines and the central nervous system. Clin Allergy Immunol 2002; 17: 337-88.
40. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788-90.
41. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513-8.
42. Dan M. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-22.
43. Garlisi CG. IL-5 inhibition as a therapy for allergic disease. Pulm Pharmacol Ther 1999; 12: 81-5.
44. Func CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294: 1871-5.
45. Func CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nature Rev Drug Discov 2005; 4: 664-72.
46. Barnes NC, Piper PJ, Costello JF. Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax 1984; 39: 500-4.
47. Busse W. The role and contribution of leukotrienes in asthma. Ann Allergy Asthma Immunol 1998; 81: 17-29.
48. O'Byrne PM, Israel E, Drazen JM. Antileukotrienes in the treatment of asthma. Ann Intern Med 1997; 127: 472-80.
49. 4 in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol 1989; 84: 19-26.
50. Bisgaard H. Leukotriene modifiers in pediatric asthma management. Pediatrics 2001; 107: 381-90.
51. MacFarlane AJ, Dworski R, Sheller JR, Pavord ID, Kay AB, Barnes NC. Sputum cysteinyl leukotrienes increase 24 hours after allergen inhalation in atopic asthmatics. Am J Respir Crit Care Med 2000; 161: 1553-8.
52. Dahlen SE, Bjork J, Hedqvist P. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary veinules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci 1981; 78: 3887-91.
53. Kim KC, Nassiri J, Brody JS. Mechanisms of airway Goblet Cell mucin release: studies with cultured tracheal surface epithelial cells. Am J Respir Cell Mol Biol 1989; 1: 137-43.
54. McGill KA, Busse WW. Zileuton. Lancet 1996; 348: 519-24.
55. Aharony D. Pharmacology of leukotriene receptor antagonists. Am J Respir Crit Care Med 1998; 157: 214-9.
56. Sampson AP and Rorde S. Combination therapy with anti-mediator drugs in allergic disease Clin Exp Allergy 2001; 31: 11-7.
57. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001; 345: 941-7.
58. Hubbard RB, Smith CJ, Smeeth L, Harrison TW, Tattersfield AE. Inhaled corticosteroids and hip fracture: a population based case control study. Am J Respir Crit Care Med 2002; 166: 1563-6.
59. Walsh LJ, Lewis SA, Wong CA, Cooper S, Oborne J, Cawte SA, et al. The impact of oral corticosteroid use on bone mineral density and vertebral fracture. Am J Respir Crit Care Med 2002; 166: 691-5.
60. Wenzel SE, Szefler SJ, Leung DYM, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997; 156: 737-43.
61. Azevedo I, de Blic J, Scheinmann P, Vargaftig BB, Bachelet M. Enhanced arachidonic acid metabolism in alveolar macrophages from wheezy infants: modulation by dexamethasone. Am J Respir Crit Care Med 1995; 152: 1208-14.
62. Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ 2003; 326: 621-6.
63. Singh M, Kumar L, Ramanathan RMLP. Consensus guidelines on management of childhood asthma in India. Indian Pediatr 1999; 36: 157-65.
64. The British guideline on asthma management review and position statement. Thorax 1997; 52: 1-21.
65. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma: update on selected topics-2002. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH publication 2003; 2: 5074.
66. Global Initiative for Asthma. Global strategy for asthma management and prevention.2002.Bethesda,MD: National Heart,Lung and Blood Institute:NIH Publication 2002. Available from: www.ginasthma.com
67. National Asthma Education and Prevention Program. Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health. NIH publication 1997; 97-4051.
68. Johnson M. The preclinical pharmacology of salmeterol: bronchodilator effects. Eur Respir Rev 1991; 1: 253-6.
69. Busse W, Koenig SM, Oppenheimer J, Sahn SA, Yancey SW, Reilly D, et al. Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily. J Allergy Clin Immunol 2003; 111: 57-65.
70. O'Byrne PM, Barnes PJ, Rodriguez-roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al., Low Dose Inhaled Budesonide and Formoterol in Mild Persistent Asthma. Am J Respir Crit Care Med 2001; 164: 1392-7.
71. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne PM, Barnes PJ, et al. Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma. New Eng J Med 1997; 337: 1405-11.
72. Lemanske RF Jr, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001; 285: 2594-603.
73. 2-agonists and corticosteroids. Eur Respir J 2002; 19: 182-91.
74. Mayers I, Damant R. Role of combination inhaled corticosteroids and long acting beta agonists in the treatment of adult asthma. Issues Emerg Health Technol 2005; 68: 1-4.
75. Azis I, Wilson AM, and Lipworth BJ. Effects of once-daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults. Chest 2000; 118: 1049-59.
76. Kips JC, O'connor BJ, Inman MD, Svensson K, Pauwels RA, and O'byrne PM. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161: 996-1001.
77. Bergmann KC, Lindemann L, Braun R, Steinkamp G. Salmeterol/fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma. Swiss Med Wkly 2004; 134: 50-8.
78. Knobil K, Yancey S, Kral K, Rickard K. Salmeterol Multi-center Asthma Research Trial (SMART): results from an interim analysis (Abstract). Chest 2003; 124: 335.
79. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeteraol. Chest 2006; 129: 15-26.
80. Aaronson DW. The "black box" Warning and allergy Drugs. J Allergy & Clin Immun 2006; 117: 40-4.
81. Kanniess F, Richter K, Böhme S, Jorres RA, Magnussen H. Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J 2002; 20: 853-8.
82. Richter K, Grönke L, Janicki S, Hermann R, Virnkaes C, Magnussen H. Protective effect of azelastine, montelukast, and their combination on early and late phase of allergen induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med 2001; 163: 430.
83. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340: 197-206.
84. Lofdahl CG, Reiss TF, Leff LA, Israel E, Noonam MJ, Finn AF, et al. Randomized, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319: 87-90.
85. Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med 1999; 155: 1235-40.
86. Vaquerizo MJ, Casan P, Castillo J, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003; 58: 204-10.
87. Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58: 211-6.
88. Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003; 327: 891-6.
89. Gendo K, Lodewick MJ. Asthma economics: focusing on therapies that improve costly outcomes. Curr Opin Pulm Med 2005; 11: 43-50.
90. Bensch G, Prenner BM. Combination therapy: appropriate for everyone? J Asthma 2003; 40: 431-44.
91. Chung KF, Adcock IM. Combination therapy of long-acting beta2-adrenoceptor agonists. Treat Respir Med 2004; 3: 279-89.
92. Nelson HS. Combination therapy of long-acting beta agonists and inhaled corticosteroids in the management of chronic asthma. Curr Allergy Asthma Rep 2005; 5: 123-9.
93. Markham A, Adkins JC. Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma. Pharmacoeconomics 2000; 18: 591-608.
94. Lyseng-Williamson KA, Plosker GL. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma. Pharmacoeconomics 2003; 21: 951-89.
95. Campbell DA, Robinson DS. Cost advantages of combination asthma therapy. Treat Respir Med 2004; 3: 133-7.
96. Cleland J, Thomas M, Price D. Pharmacoeconomics of asthma treatment. Expert Opin Pharmacother 2003; 4: 311-8.
97. Stoloff S, Poinsett-Holmes K, Dorinsky PM. Combination therapy with inhaled long-acting beta2-agonists and inhaled corticosteroids: a paradigm shift in asthma management. Pharmacotherapy 2002; 22: 212-26.
98. Miyagawa T, Arakawa I, Shiragami M, Nishimura S. Cost-effectiveness of including salmeterol in asthma therapy in a primary care setting in Japan. Yakugaku Zasshi 2006; 26: 51-9.
99. Pieters WR, Wilson KK, Smith HC, Tamminga JJ, Sondhi S. Salmeterol/ fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma. Treat Respir Med 2005; 4: 129-38.
100. Reynolds NA, Lyseng-Williamson KA, Wiseman LR. Inhaled salmeterol/ fluticasone propionate: a review of its use in asthma. Drugs 2005; 65: 1715-34.
101. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment). Allergy 2005; 60: 309-16.
102. Boushey HA, Jr. Experiences with monoclonal antibody therapy for allergic asthma. J Allergy Clin Immunol 2001; 108(2 Suppl): 77-83.
103. Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254-61.
104. Buhl R, Solèr M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002; 20: 73-8.
105. Recchia G, Carlie GD. Quality of Life and drug therapy. In Stepsons MDB, Talbot JCC, Routledge PA, Eds. Detection of New Adverse Drug Reactions. London; Macmillan Reference Ltd, 1999; 131-47.
106. Kremer B. Quality of life scales in allergic rhinitis. Curr Opin Allergy Clin Immunol 2004; 4: 171-6.
107. Juniper EF, Jenkins C, Price MJ, James MH. Impact of inhaled salmeterol/ fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma. Am J Respir Med 2002; 1: 435-40.
108. Vegazo GO, Martin FJ, Barcina SC, Jimenez FJ, Estiarte NR. Impact of the long active beta-2 agonists inhaled therapy on the quality of life in asthmatic patients. Ann Med Interna 2004; 21: 272-8.
109. Nathan RA, Dorinsky P, Rosenzweig JR, Shah T, Edin H, Prillaman B. Improved ability to perform strenuous activities after treatment with fluticasone propionate/salmeterol combination in patients with persistent asthma. J Asthma 2003; 40: 815-22.
110. Chuchalin AG, Svensson K, Stahl E, et al. A health-related quality-of-life comparison of formoterol (Oxis) Turbuhaler plus budesonide (Pulmicort) Turbuhaler with budesonide Turbuhaler alone and noncorticosteroid treatment in asthma: a randomized clinical study in Russia. Respiration 2002; 69: 427-33.
111. Juniper EF, Svensson K, O'Byrne PM, et al Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J 1999; 14: 1038-43.
112. Albsoul-Younes AM, Al-Doghim IA, Al-Safi SA, Najada AS. Improving quality of life in asthmatic children. Indian J Pediatr 2004; 71: 1075-8.
113. Garrelds IM, Veld TG, Toorenenbergen AW, et al. Selective effect of levocabastine on histamine receptor and histamine release from human leukocytes and guinea pig isolated tissue. Ann Allergy Asthma Immunol 1996; 76: 327-34.
114. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000; 106: 1088-95.
115. Dahlen SE, Malmstrom D, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized double-blind, placebo-controlled trial. Am Respir Crit Care Med 2002; 165: 9-14.
116. Leigh R, Vethanayagam D, Yoshida M, et al. Effect of montelukast and budesonide on airway responses and airway inflammation in asthma. Am Respir Crit Care Med 2002; 166: 1212-7.
117. Roquet A, Dahlen B, Kumlin M, et al. Combined antagonism of leukotriene and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997; 155: 1856-63.
118. Wilson AM, Orr LC, Sims EJ, Dempsey OJ, Lipworth BJ. Antiasthmatic Effects of Mediator Blockade versus Topical Corticosteroids in Allergic Rhinitis and Asthma. Am J Respir Crit Care Med 2000; 162: 1297-301.
119. Laviolette M, Malmstrom K, Chervinsky SP, et al. Montelukast Added to Inhaled Beclomethasone in Treatment of Asthma. Am J Respir Crit Care Med 1999; 160: 1862-8.
120. Meltzer EO, Malmstrom K, Lu S, et al. Concomittant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000; 105: 917-22.
121. Wilson AM, Orr LC, Coutie WJR, et al. A combination of once daily fexofenadine (FEX) alone or the combination of montelukast plus loratadine (ML + LT) on symptoms and nasal peak flow in seasonal allergic rhinitis (SAR) (Abstract). J Allergy Clin Immunol 2001; 107: 1002.
122. Wilson AM, Orr LC, Sims EJ, Lipworth BJ. Effect of monotherapy with intranasal corticosteroid or combined oral antihistamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy 2001; 31: 61-8.
123. Wilson AM, Orr LC, Sims EJ, Lipworth BJ. Effect of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001; 87: 344-9.
124. Wilson AM, Dempsey OJ, Sims EJ, Coutie WJR, Paterson MC, Lipworth BJ. Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow. Clin Exp Allergy 2000; 30: 833-8.
125. Nayak AS, Philip G, Lu S, Malice MP, Reiss TF. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002; 88: 592-600.
126. Kurowski M, Kuna P, Gorski P. Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic infammation. Allergy 2004; 59: 280-8.